Sepsis — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Sepsis is defined as infected patients with a rise of ≥2 Sequential Organ Failure Score (SOFA) points. Microorganisms in sepsis carry specific pathogen-associated molecular patterns, binding to pattern recognition receptors (PRRs), triggering immune cells to produce proinflammatory cytokines. Another PRR stimulation mechanism is the damage-associated pathogen pattern, resulting from molecular particle release due to invasive microbes causing cell damage. PRR binding releases pro-inflammatory and anti-inflammatory mediators, contributing to tissue damage and compromised immune response. Compliance with sepsis bundles can be challenging due to the complexity of identifying and treating sepsis. In the United States, sepsis is the leading cause of inpatient death, impacting 1.7 million adults annually and contributing to 270,000 deaths, accounting for about 20% of global annual deaths. The rising incidence of sepsis is attributed to factors such as antibiotic resistance, an aging population, and increased use of invasive procedures. Predisposing factors to septic shock include cancer, immunodeficiency, chronic organ failure, and genetic factors. Early detection, facilitated by screening tools, is crucial for improved patient outcomes. Routine screening for sepsis, especially in patients admitted for severe infections, is essential for early diagnosis and prompt therapy implementation. Specialized sepsis screening tools for ICU care have been developed to expedite this process, emphasizing the critical importance of reducing the time to diagnosis for all patients.
Thelansis’s “Sepsis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sepsis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Sepsis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Sepsis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
